Navigation Links
Apexigen Announces Initiation of Clinical Trials By Its Partner, Simcere Pharmaceutical Group
Date:11/11/2012

BURLINGAME, Calif., Nov. 11, 2012 /PRNewswire/ -- Apexigen, an emerging biopharmaceutical company dedicated to the discovery and development of best-in-class therapeutic monoclonal antibodies, announced today that its partner, Simcere Pharmaceutical Group (NYSE: SCR) of Nanjing, received approval from the State Food and Drug Administration of China to begin first-in-man trials with APX003, which is also known as BD0801, for the treatment of cancer. With this approval, APX003/BD0801 becomes the first humanized monoclonal antibody derived from Apexigen's proprietary antibody technology platform to enter human trials.

APX003/BD0801 is being developed in China through an active partnership between Apexigen and Simcere.  Apexigen has collaborated with Simcere to add its antibody development expertise and experience to the advancement of the APX003/BD0801 program. This approval marks the success of the dedicated work of the collaboration team to file and defend an IND application, and initiates the next phase of collaboration in clinical development.

"We're very pleased to see the IND approval for APX003/BD0801.  This is an important milestone for our collaboration with Simcere and for proof-of-concept of our antibody technology platform" said Dr. Xiaodong Yang, President & CEO.  "We look forward to continuing the collaboration with Simcere and advancing AXP003/BD0801 into clinical development."

APX003/BD0801 is a humanized monoclonal antibody directed against VEGF and is under development for the treatment of multiple malignancies.

About Apexigen, Inc.
Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company's proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previously inaccessible disease targets.

Apexigen is actively pursuing product development, both by itself and in collaboration with partners, with a focus in oncology. The company's product portfolio is comprised of humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease.

Collaboration is an important aspect of Apexigen's business model. At present, seven corporate collaborations are in place, representing both product development collaborations and antibody technology collaborations. Through the building of successful collaborations, Apexigen is able to develop a broad base of antibody products and promote wider use of its antibody technology platform. Additional information is available at www.apexigen.com.

Contact:
Mark Nevins
Vice President, Business Development
(650) 931-6236 ext 502
mnevins@apexigen.com

 


'/>"/>
SOURCE Apexigen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... India , April 27, 2016 ... market research report with specific focus on US, ... Japan , to the healthcare business ... research library. Complete report on the ... 11 companies and supported with 282 tables and ...
(Date:4/26/2016)... Redwood City, CA (PRWEB) , ... April 26, ... ... company for healthcare, today announced that Ardy Arianpour has joined the company as ... 14 years of experience bringing innovative genomic technologies to market, was most recently ...
(Date:4/26/2016)... ... April 26, 2016 , ... Heidelberg Instruments, a leader ... innovation for its Volume Pattern Generator (VPG) line of lithography systems. The breakthrough ... as well as a solution for mid volume direct write lithography applications. ...
(Date:4/26/2016)... ... 2016 , ... This unique "Fertility Happy Hour" event will be held at ... get the lowdown on female fertility and the reproductive technologies that are empowering a ... Boston IVF - The Arizona Center, will give a short presentation and answer ...
Breaking Biology Technology:
(Date:3/10/2016)... , March 10, 2016 ... market research report "Identity and Access Management Market by ... Compliance, and Governance), by Organization Size, by Deployment, by ... published by MarketsandMarkets, The market is estimated to grow ... Billion by 2020, at a Compound Annual Growth Rate ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
(Date:3/2/2016)... , March 2, 2016 ... addition of the "Global Biometrics as ... their offering. --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> Research and Markets ( ...
Breaking Biology News(10 mins):